Published 1988
| Version v1
Book
Dose fractionation in neutron capture therapy for malignant melanoma
Creators
- 1. Australian Nuclear Science and Technology Organization, Menai, New South Wales
Description
Australia is entering a joint clinical trial with Japan for thermal neutron capture therapy of selected patients with superficial local recurrent, local advanced and isolated metastatic malignant melanoma. The para-boronophenylalanine (BPA) compound will be used with a neutron fluence of about 1013 neutrons per cm2, to be delivered in a single dose. While in the initial trials of NCT, the single dose is a practical procedure; there may be advantages in dose fractionation, and these are considered in this paper
Additional details
Publishing Information
- Publisher
- Plenum Press.
- Imprint Place
- New York, NY (USA)
- Imprint Title
- Clinical aspects of neutron capture therapy
- Imprint Pagination
- 370 p.
- Journal Page Range
- p. 63-67.
Conference
- Title
- Workshop on clinical aspects of Boron Neutron Capture Theory (BNCT).
- Dates
- 1-2 Feb 1988.
- Place
- Upton, NY (USA).
INIS
- Country of Publication
- United States
- Country of Input or Organization
- United States
- INIS RN
- 21003007
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Conference
- Descriptors DEI
- AUSTRALIA; BORON COMPOUNDS; FRACTIONATED IRRADIATION; INTERNATIONAL COOPERATION; JAPAN; MELANOMAS; METASTASES; NEUTRON CAPTURE THERAPY; RADIATION DOSES
- Descriptors DEC
- ASIA; AUSTRALASIA; COOPERATION; DEVELOPED COUNTRIES; DISEASES; IRRADIATION; MEDICINE; NEOPLASMS; NEUTRON THERAPY; RADIOTHERAPY; THERAPY
Optional Information
- Secondary number(s)
- CONF-8802102--.